Clinical Trial Update: A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

This document summarizes a completed Phase 1 study of JNS002 (doxorubicin hydrochloride liposome injection) in relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• JNS002 (Doxorubicin Hydrochloride Liposome Injection)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED